Recent Emerging Trend in Stem Cell Therapy Risk Factors

Bahareh      Pourjabbar; Forough      Shams; Maryam      Moghadam; Milad      Ahani-Nahayati; Arezo      Azari; Farshid      Sefat; Saeed   Heidari   Keshel
Abstract

Different types of stem cells have remarkable characteristics such as high proliferation rate, multi/pluripotency, self-renewal, and broad differentiation that can effectively treat diseases, cancers, and damage. Despite abundant therapeutic applications of stem cells in medical science, numerous risks threaten stem cell transplantation. Tumor development, immune response, cellular senescence, dosage effects, and administration timing are critical risks that should be considered in stem cell therapy. Hence, an investigation of possible risks is required before utilizing stem cell-based medicinal products in the clinical phase and human trials. This review aims to survey the literature and perspectives on the advantages and risks associated with pluripotent and multipotent stem cells.
Graphical Abstract

[1]
Zakrzewski W, Dobrzyński M, Szymonowicz M, Rybak Z. Stem cells: Past, present, and future. Stem Cell Res Ther  2019; 10(1): 68.
 [http://dx.doi.org/10.1186/s13287-019-1165-5]

[2]
Cheng N, Yao H-l, Reid LM. Hepatic stem cells: Lineage biology and pluripotency. In: Principles of Regenerative Medicine.  Burlington, USA: Elsevier 2008; p. 344.

[3]
Wobus AM, Boheler KR. Embryonic stem cells: Prospects for developmental biology and cell therapy. Physiol Rev  2005; 85(2): 635-78.
 [http://dx.doi.org/10.1152/physrev.00054.2003]

[4]
Alonso-Goulart V, Ferreira LB, Duarte CA, et al. Mesenchymal stem cells from human adipose tissue and bone repair: A literature review. Biotechnol Res Innovat  2018; 2(1): 74-80.
 [http://dx.doi.org/10.1016/j.biori.2017.10.005]

[5]
Seale P, Asakura A, Rudnicki MA. The potential of muscle stem cells. Dev Cell  2001; 1(3): 333-42.
 [http://dx.doi.org/10.1016/S1534-5807(01)00049-1]

[6]
Choi EW. Adult stem cell therapy for autoimmune disease. Int J Stem Cells  2009; 2(2): 122-8.
 [http://dx.doi.org/10.15283/ijsc.2009.2.2.122]

[7]
Chu DT, Nguyen TT, Tien NLB, et al. Recent progress of stem cell therapy in cancer treatment: Molecular mechanisms and potential applications. Cells  2020; 9(3): 563.
 [http://dx.doi.org/10.3390/cells9030563]

[8]
Gupta PK, Das AK, Chullikana A, Majumdar AS. Mesenchymal stem cells for cartilage repair in osteoarthritis. Stem Cell Res Ther  2012; 3(4): 25.
 [http://dx.doi.org/10.1186/scrt116]

[9]
Nandoe Tewarie RS, Hurtado A, Bartels RH, Grotenhuis A, Oudega M. Stem cell-based therapies for spinal cord injury. J Spinal Cord Med  2009; 32(2): 105-14.

[10]
Kim JH, Lee S-R, Song YS, Lee HJ. Stem cell therapy in bladder dysfunction: Where are we? And where do we have to go? Biomed Res Int  2013; 930713.
 [http://dx.doi.org/10.1155/2013/930713]

[11]
Pourjabbar B, Biazar E, Heidari Keshel S, Ahani-Nahayati M, Baradaran-Rafii A, Roozafzoon R, et al. Bio-polymeric hydrogels for regeneration of corneal epithelial tissue. Int J Polym Mater Polym Biomater  2021; 1-18.

[12]
Ahani-Nahayati M, Niazi V, Moradi A, et al. Cell-based therapy for ocular disorders: A promising frontier. Curr Stem Cell Res Ther  2021; 17(2): 147-65.

[13]
Mezey É, Nemeth K. Mesenchymal stem cells and infectious diseases: Smarter than drugs. Immunol Lett  2015; 168(2): 208-14.
 [http://dx.doi.org/10.1016/j.imlet.2015.05.020]

[14]
Hassan AU, Hassan G, Rasool Z. Role of stem cells in treatment of neurological disorder. Int J Health Sci  2009; 3(2): 227.

[15]
Chanda D, Isayeva T, Kumar S, et al. Therapeutic potential of adult bone marrow–derived mesenchymal stem cells in prostate cancer bone metastasis. Clin Cancer Res  2009; 15(23): 7175-85.
 [http://dx.doi.org/10.1158/1078-0432.CCR-09-1938]

[16]
Pontikoglou C, Deschaseaux F, Sensebé L, Papadaki HA. Bone marrow mesenchymal stem cells: Biological properties and their role in hematopoiesis and hematopoietic stem cell transplantation. Stem Cell Rev  2011; 7(3): 569-89.
 [http://dx.doi.org/10.1007/s12015-011-9228-8]

[17]
Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy  2006; 8(4): 315-7.
 [http://dx.doi.org/10.1080/14653240600855905]

[18]
Ebelt H, Jungblut M, Zhang Y, et al. Cellular cardiomyoplasty: Improvement of left ventricular function correlates with the release of cardioactive cytokines. Stem Cells  2007; 25(1): 236-44.
 [http://dx.doi.org/10.1634/stemcells.2006-0374]

[19]
Di Nicola M, Carlo-Stella C, Magni M, et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood  2002; 99(10): 3838-43.
 [http://dx.doi.org/10.1182/blood.V99.10.3838]

[20]
Miao C, Lei M, Hu W, Han S, Wang Q. A brief review: The therapeutic potential of bone marrow mesenchymal stem cells in myocardial infarction. Stem Cell Res Ther  2017; 8(1): 242.
 [http://dx.doi.org/10.1186/s13287-017-0697-9]

[21]
Mohamed-Ahmed S, Fristad I, Lie SA, et al. Adipose-derived and bone marrow mesenchymal stem cells: A donor-matched comparison. Stem Cell Res Ther  2018; 9(1): 168.
 [http://dx.doi.org/10.1186/s13287-018-0914-1]

[22]
Beane OS, Darling EM. Isolation, characterization, and differentiation of stem cells for cartilage regeneration. Ann Biomed Eng  2012; 40(10): 2079-97.
 [http://dx.doi.org/10.1007/s10439-012-0639-8]

[23]
Kowal JM, Möller S, Ali D, et al. Identification of a clinical signature predictive of differentiation fate of human bone marrow stromal cells. Stem Cell Res Ther  2021; 12(1): 265.
 [http://dx.doi.org/10.1186/s13287-021-02338-1]

[24]
Rodríguez-Lozano FJ, Oñate-Sánchez R, Gonzálvez-García M, et al. Allogeneic bone marrow mesenchymal stem cell transplantation in tooth extractions sites ameliorates the incidence of osteonecrotic jaw-like lesions in zoledronic acid-treated rats. J Clin Med  2020; 9(6): 1649.
 [http://dx.doi.org/10.3390/jcm9061649]

[25]
Kaibuchi N, Iwata T, Okamoto T, Kawase-Koga Y, Yamato M. Cell therapy for medication-related osteonecrosis of the jaw: Update on treatment strategies. Eur Cell Mater  2021; 41: 31-9.
 [http://dx.doi.org/10.22203/eCM.v041a03]

[26]
Anzalone R, Opatrilova R, Kruzliak P, Gerbino A, La Rocca G. Mesenchymal stromal cells from wharton’s jelly (WJ-MSCs): Coupling their hidden differentiative program to their frank immunomodulatory phenotype Perinatal Stem Cells.  Elsevier 2018; pp. 271-9.

[27]
Anzalone R, Iacono ML, Corrao S, et al. New emerging potentials for human wharton’s jelly mesenchymal stem cells: Immunological features and hepatocyte-like differentiative capacity. Stem Cells Dev  2010; 19(4): 423-38.
 [http://dx.doi.org/10.1089/scd.2009.0299]

[28]
Charbord P. Bone marrow mesenchymal stem cells: Historical overview and concepts. Hum Gene Ther  2010; 21(9): 1045-56.
 [http://dx.doi.org/10.1089/hum.2010.115]

[29]
Pourjabbar B, Latifi P, Soleimani M, Jamaati H, Hashemian SM, Mortazavi SM. Cell therapy based SARS-cov 2-2019 managements: A literature review. Regen Reconstr Restor  2020; 5: e7.

[30]
Nitkin CR, Bonfield TL. Concise review: Mesenchymal stem cell therapy for pediatric disease: perspectives on success and potential improvements. Stem Cells Transl Med  2017; 6(2): 539-65.
 [http://dx.doi.org/10.5966/sctm.2015-0427]

[31]
Dai R, Wang Z, Samanipour R, Koo K-I, Kim K. Adipose-derived stem cells for tissue engineering and regenerative medicine applications. Stem Cells Int  2016; 6737345.
 [http://dx.doi.org/10.1155/2016/6737345]

[32]
Wankhade UD, Shen M, Kolhe R, Fulzele S. Advances in adipose-derived stem cells isolation, characterization, and application in regenerative tissue engineering. Stem Cells Int  2016; 3206807.
 [http://dx.doi.org/10.1155/2016/3206807]

[33]
Zuk PA, Zhu M, Mizuno H, et al. Multilineage cells from human adipose tissue: Implications for cell-based therapies. Tissue Eng  2001; 7(2): 211-28.
 [http://dx.doi.org/10.1089/107632701300062859]

[34]
Miana VV, Prieto GEA. Adipose tissue stem cells in regenerative medicine. Ecancermedicalscience  2018; 12: 12.
 [http://dx.doi.org/10.3332/ecancer.2018.822]

[35]
McIntosh K, Zvonic S, Garrett S, et al. The immunogenicity of human adipose‐derived cells: Temporal changes in vitro. Stem Cells  2006; 24(5): 1246-53.
 [http://dx.doi.org/10.1634/stemcells.2005-0235]

[36]
Hass R, Kasper C, Böhm S, Jacobs R. Different populations and sources of human mesenchymal stem cells (MSC): A comparison of adult and neonatal tissue-derived MSC. Cell Commun Signal  2011; 9(1): 12.
 [http://dx.doi.org/10.1186/1478-811X-9-12]

[37]
Law S, Chaudhuri S. Mesenchymal stem cell and regenerative medicine: Regeneration versus immunomodulatory challenges. Am J Stem Cells  2013; 2(1): 22.

[38]
Pigott JH, Ishihara A, Wellman ML, Russell DS, Bertone AL. Investigation of the immune response to autologous, allogeneic, and xenogeneic mesenchymal stem cells after intra-articular injection in horses. Vet Immunol Immunopathol  2013; 156(1-2): 99-106.
 [http://dx.doi.org/10.1016/j.vetimm.2013.09.003]

[39]
Majka M, Sułkowski M, Badyra B. Regeneration of ischemic cardiovascular damage using wharton’s jelly as an unlimited source of therapeutic stem cells. In: Perinatal Stem Cells.  Academic Press 2018; pp. 281-9.

[40]
Chen G, Yue A, Ruan Z, et al. Human umbilical cord-derived mesenchymal stem cells do not undergo malignant transformation during long-term culturing in serum-free medium. PLoS One  2014; 9(6): e98565.
 [http://dx.doi.org/10.1371/journal.pone.0098565]

[41]
Sadlik B, Jaroslawski G, Puszkarz M, et al. Cartilage repair in the knee using umbilical cord wharton’s jelly–derived mesenchymal stem cells embedded onto collagen scaffolding and implanted under dry arthroscopy. Arthrosc Tech  2018; 7(1): e57-63.
 [http://dx.doi.org/10.1016/j.eats.2017.08.055]

[42]
Najar M, Raicevic G, Jebbawi F, et al. Characterization and functionality of the CD200–CD200R system during mesenchymal stromal cell interactions with T-lymphocytes. Immunol Lett  2012; 146(1-2): 50-6.
 [http://dx.doi.org/10.1016/j.imlet.2012.04.017]

[43]
Kögler G, Sensken S, Airey JA, et al. A new human somatic stem cell from placental cord blood with intrinsic pluripotent differentiation potential. J Exp Med  2004; 200(2): 123-35.
 [http://dx.doi.org/10.1084/jem.20040440]

[44]
Ahani-Nahayati M, Niazi V, Moradi A, et al. Umbilical cord mesenchymal stem/stromal cells potential to treat organ disorders; an emerging strategy. Curr Stem Cell Res Ther  2021; 17(2): 126-46.

[45]
Degistirici Ö, Jäger M, Knipper A. Applicability of cord blood-derived unrestricted somatic stem cells in tissue engineering concepts. Cell Prolif  2008; 41(3): 421-40.
 [http://dx.doi.org/10.1111/j.1365-2184.2008.00536.x]

[46]
Zeinali R, Biazar E, Keshel SH, Tavirani MR, Asadipour K. Regeneration of full-thickness skin defects using umbilical cord blood stem cells loaded into modified porous scaffolds. ASAIO J  2014; 60(1): 106-14.
 [http://dx.doi.org/10.1097/MAT.0000000000000025]

[47]
Liao Y, Itoh M, Yang A, et al. Human cord blood-derived unrestricted somatic stem cells promote wound healing and have therapeutic potential for patients with recessive dystrophic epidermolysis bullosa. Cell Transplant  2014; 23(3): 303-17.
 [http://dx.doi.org/10.3727/096368913X663569]

[48]
Kögler G, Radke TF, Lefort A, et al. Cytokine production and hematopoiesis supporting activity of cord blood–derived unrestricted somatic stem cells. Exp Hematol  2005; 33(5): 573-83.
 [http://dx.doi.org/10.1016/j.exphem.2005.01.012]

[49]
Evans MJ, Kaufman MH. Establishment in culture of pluripotential cells from mouse embryos. Nature  1981; 292(5819): 154-6.

[50]
Martin GR. Isolation of a pluripotent cell line from early mouse embryos cultured in medium conditioned by teratocarcinoma stem cells. Proc Natl Acad Sci  1981; 78(12): 7634-8.
 [http://dx.doi.org/10.1073/pnas.78.12.7634]

[51]
Thomson JA, Itskovitz-Eldor J, Shapiro SS, et al. Embryonic stem cell lines derived from human blastocysts. Science  1998; 282(5391): 1145-7.

[52]
Boroviak T, Loos R, Bertone P, Smith A, Nichols J. The ability of inner-cell-mass cells to self-renew as embryonic stem cells is acquired following epiblast specification. Nat Cell Biol  2014; 16(6): 513-25.
 [http://dx.doi.org/10.1038/ncb2965]

[53]
Reubinoff BE, Pera MF, Fong CY, Trounson A, Bongso A. Embryonic stem cell lines from human blastocysts: Somatic differentiation in vitro. Nat Biotechnol  2000; 18(4): 399-404.
 [http://dx.doi.org/10.1038/74447]

[54]
Volarevic V, Markovic BS, Gazdic M, et al. Ethical and safety issues of stem cell-based therapy. Int J Med Sci  2018; 15(1): 36-45.
 [http://dx.doi.org/10.7150/ijms.21666]

[55]
Heidari-Keshel S, Soleimani M, Ebrahimi M, Heidari MH. Evaluation of pluripotency gene expression in mouse embryonic stem cell cultured on the human feeder layer. J Paramed Sci  2010; 1(2): 32-7.

[56]
Amit M, Margulets V, Segev H, et al. Human feeder layers for human embryonic stem cells. Biol Reprod  2003; 68(6): 2150-6.
 [http://dx.doi.org/10.1095/biolreprod.102.012583]

[57]
Keshel SH, Soleimani M, Tavirani MR, et al. Evaluation of unrestricted somatic stem cells as a feeder layer to support undifferentiated embryonic stem cells. Mol Reprod Dev  2012; 79(10): 709-18.
 [http://dx.doi.org/10.1002/mrd.22079]

[58]
Shroff G, Gupta R. Human embryonic stem cells in the treatment of patients with spinal cord injury. Ann Neurosci  2015; 22(4): 208.
 [http://dx.doi.org/10.5214/ans.0972.7531.220404]

[59]
Zhou S, Flamier A, Abdouh M, et al. Differentiation of human embryonic stem cells into cone photoreceptors through simultaneous inhibition of BMP, TGFβ and Wnt signaling. Development  2015; 142(19): 3294-306.
 [http://dx.doi.org/10.1242/dev.125385]

[60]
Shiba Y, Fernandes S, Zhu WZ, et al. Human ES-cell-derived cardiomyocytes electrically couple and suppress arrhythmias in injured hearts. Nature  2012; 489(7415): 322-5.
 [http://dx.doi.org/10.1038/nature11317]

[61]
Fernandes S, Chong JJH, Paige SL, et al. Comparison of human embryonic stem cell-derived cardiomyocytes, cardiovascular progenitors, and bone marrow mononuclear cells for cardiac repair. Stem Cell Reports  2015; 5(5): 753-62.
 [http://dx.doi.org/10.1016/j.stemcr.2015.09.011]

[62]
Vedantham V. New approaches to biological pacemakers: Links to sinoatrial node development. Trends Mol Med  2015; 21(12): 749-61.
 [http://dx.doi.org/10.1016/j.molmed.2015.10.002]

[63]
Avior Y, Levy G, Zimerman M, et al. Microbial‐derived lithocholic acid and vitamin K 2 drive the metabolic maturation of pluripotent stem cells–derived and fetal hepatocytes. Hepatology  2015; 62(1): 265-78.
 [http://dx.doi.org/10.1002/hep.27803]

[64]
Tolosa L, Caron J, Hannoun Z, et al. Transplantation of hESC-derived hepatocytes protects mice from liver injury. Stem Cell Res Ther  2015; 6(1): 246.
 [http://dx.doi.org/10.1186/s13287-015-0227-6]

[65]
Carpentier A, Nimgaonkar I, Chu V, Xia Y, Hu Z, Liang TJ. Hepatic differentiation of human pluripotent stem cells in miniaturized format suitable for high-throughput screen. Stem Cell Res  2016; 16(3): 640-50.
 [http://dx.doi.org/10.1016/j.scr.2016.03.009]

[66]
Bruin JE, Saber N, Braun N, et al. Treating diet-induced diabetes and obesity with human embryonic stem cell-derived pancreatic progenitor cells and antidiabetic drugs. Stem Cell Reports  2015; 4(4): 605-20.
 [http://dx.doi.org/10.1016/j.stemcr.2015.02.011]

[67]
Salguero-Aranda C, Tapia-Limonchi R, Cahuana GM, et al. Differentiation of mouse embryonic stem cells toward functional pancreatic β-cell surrogates through epigenetic regulation of Pdx1 by nitric oxide. Cell Transplant  2016; 25(10): 1879-92.
 [http://dx.doi.org/10.3727/096368916X691178]

[68]
Cheng A, Kapacee Z, Peng J, et al. Cartilage repair using human embryonic stem cell‐derived chondroprogenitors. Stem Cells Transl Med  2014; 3(11): 1287-94.
 [http://dx.doi.org/10.5966/sctm.2014-0101]

[69]
Goldthwaite CA Jr. (2016) The promise of induced pluripotent stem cells (iPSCs). National Institutes of Health, U.S. Department of Health and Human Services. https://stemcells.nih.gov/info/Regenerative_ Medicine/2006Chapter10.htm

[70]
Kumar D, Anand T, Kues WA. Clinical potential of human-induced pluripotent stem cells. Cell Biol Toxicol  2017; 33(2): 99-112.
 [http://dx.doi.org/10.1007/s10565-016-9370-9]

[71]
Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell  2006; 126(4): 663-76.

[72]
Okita K, Ichisaka T, Yamanaka S. Generation of germline-competent induced pluripotent stem cells. Nature  2007; 448(7151): 313-7.

[73]
Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell  2007; 131(5): 861-72.

[74]
Yu J, Vodyanik MA, Smuga-Otto K, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science  2007; 318(5858): 1917-20.

[75]
Nagoshi N, Tsuji O, Nakamura M, Okano H. Cell therapy for spinal cord injury using induced pluripotent stem cells. Regen Ther  2019; 11: 75-80.
 [http://dx.doi.org/10.1016/j.reth.2019.05.006]

[76]
Daley GQ, Lensch MW, Jaenisch R, Meissner A, Plath K, Yamanaka S. Broader implications of defining standards for the pluripotency of iPSCs. Cell Stem Cell  2009; 4(3): 200-1.
 [http://dx.doi.org/10.1016/j.stem.2009.02.009]

[77]
Herberts CA, Kwa MSG, Hermsen HPH. Risk factors in the development of stem cell therapy. J Transl Med  2011; 9(1): 29.
 [http://dx.doi.org/10.1186/1479-5876-9-29]

[78]
Master Z, McLeod M, Mendez I. Benefits, risks and ethical considerations in translation of stem cell research to clinical applications in Parkinson’s disease. J Med Ethics  2007; 33(3): 169-73.
 [http://dx.doi.org/10.1136/jme.2005.013169]

[79]
Elgaz S, Kuçi Z, Kuçi S, Bönig H, Bader P. Clinical use of mesenchymal stromal cells in the treatment of acute graft-versus-host disease. Transfus Med Hemother  2019; 46(1): 27-34.
 [http://dx.doi.org/10.1159/000496809]

[80]
Trento C, Bernardo ME, Nagler A, et al. Manufacturing mesenchymal stromal cells for the treatment of graft-versus-host disease: A survey among centers affiliated with the European Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant  2018; 24(11): 2365-70.
 [http://dx.doi.org/10.1016/j.bbmt.2018.07.015]

[81]
Ohm JE, Mali P, Van Neste L, et al. Cancer-related epigenome changes associated with reprogramming to induced pluripotent stem cells. Cancer Res  2010; 70(19): 7662-73.
 [http://dx.doi.org/10.1158/0008-5472.CAN-10-1361]

[82]
Mousavinejad M, Andrews PW, Shoraki EK. Current biosafety considerations in stem cell therapy. Cell J (Yakhteh)  2016; 18(2): 281.

[83]
Lee AS, Tang C, Rao MS, Weissman IL, Wu JC. Tumorigenicity as a clinical hurdle for pluripotent stem cell therapies. Nat Med  2013; 19(8): 998-1004.
 [http://dx.doi.org/10.1038/nm.3267]

[84]
Tan Y, Ooi S, Wang L. Immunogenicity and tumorigenicity of pluripotent stem cells and their derivatives: Genetic and epigenetic perspectives. Curr Stem Cell Res Ther  2013; 9(1): 63-72.
 [http://dx.doi.org/10.2174/1574888X113086660068]

[85]
Haase A, Olmer R, Schwanke K, et al. Generation of induced pluripotent stem cells from human cord blood. Cell Stem Cell  2009; 5(4): 434-41.
 [http://dx.doi.org/10.1016/j.stem.2009.08.021]

[86]
Martin U. Therapeutic application of pluripotent stem cells: Challenges and risks. Front Med  2017; 4: 229.
 [http://dx.doi.org/10.3389/fmed.2017.00229]

[87]
Prokhorova TA, Harkness LM, Frandsen U, et al. Teratoma formation by human embryonic stem cells is site dependent and enhanced by the presence of Matrigel. Stem Cells Dev  2009; 18(1): 47-54.
 [http://dx.doi.org/10.1089/scd.2007.0266]

[88]
Kroon E, Martinson LA, Kadoya K, et al. Pancreatic endoderm derived from human embryonic stem cells generates glucose-responsive insulin-secreting cells in vivo. Nat Biotechnol  2008; 26(4): 443-52.
 [http://dx.doi.org/10.1038/nbt1393]

[89]
Liu X, Li W, Fu X, Xu Y. The immunogenicity and immune tolerance of pluripotent stem cell derivatives. Front Immunol  2017; 8: 645.
 [http://dx.doi.org/10.3389/fimmu.2017.00645]

[90]
Khandany B, Heidari MM, Khatami M. Induced pluripotent stem cells (iPSCs) based approaches for hematopoietic cancer therapy. Iran J Pediatr Hematol Oncol  2019; 9(2): 117-30.
 [http://dx.doi.org/10.18502/ijpho.v9i2.611]

[91]
Saldanha S, Royston K, Udayakumar N, Tollefsbol T. Epigenetic regulation of epidermal stem cell biomarkers and their role in wound healing. Int J Mol Sci  2015; 17(1): 16.
 [http://dx.doi.org/10.3390/ijms17010016]

[92]
Luo Y, Liu C, Cerbini T, et al. Stable enhanced green fluorescent protein expression after differentiation and transplantation of reporter human induced pluripotent stem cells generated by AAVS1 transcription activator‐like effector nucleases. Stem Cells Transl Med  2014; 3(7): 821-35.
 [http://dx.doi.org/10.5966/sctm.2013-0212]

[93]
Zhang CL, Huang T, Wu BL, He WX, Liu D. Stem cells in cancer therapy: Opportunities and challenges. Oncotarget  2017; 8(43): 75756-66.
 [http://dx.doi.org/10.18632/oncotarget.20798]

[94]
Schriebl K, Satianegara G, Hwang A, et al. Selective removal of undifferentiated human embryonic stem cells using magnetic activated cell sorting followed by a cytotoxic antibody. Tissue Eng Part A  2012; 18(9-10): 899-909.
 [http://dx.doi.org/10.1089/ten.tea.2011.0311]

[95]
Xu G, McLeod HL. Strategies for enzyme/prodrug cancer therapy. Clin Cancer Res  2001; 7(11): 3314-24.

[96]
Malecki M, LaVanne C, Alhambra D, Dodivenaka C, Nagel S, Malecki R. Safeguarding stem cell-based regenerative therapy against iatrogenic cancerogenesis: Transgenic expression of DNASE1, DNASE1L3, DNASE2, DFFB controlled by POLA1 promoter in proliferating and directed differentiation resisting human autologous pluripotent induced stem cells leads to their death. Stem Cell Res Ther  2013; (5): 21559.

[97]
Patel M, Yang S. Advances in reprogramming somatic cells to induced pluripotent stem cells. Stem Cell Rev  2010; 6(3): 367-80.
 [http://dx.doi.org/10.1007/s12015-010-9123-8]

[98]
Kim JB, Zaehres H, Wu G, Gentile L, Ko K, Sebastiano V, et al. Pluripotent stem cells induced from adult neural stem cells by reprogramming with two factors. Nature  2008; 454(7204): 646-50.

[99]
Loh YH, Wu Q, Chew JL, et al. The Oct4 and nanog transcription network regulates pluripotency in mouse embryonic stem cells. Nat Genet  2006; 38(4): 431-40.
 [http://dx.doi.org/10.1038/ng1760]

[100]
Wernig M, Meissner A, Foreman R, et al. In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state. Nature  2007; 448(7151): 318-24.

[101]
Ben-David U, Benvenisty N. The tumorigenicity of human embryonic and induced pluripotent stem cells. Nat Rev Cancer  2011; 11(4): 268-77.
 [http://dx.doi.org/10.1038/nrc3034]

[102]
Goldring CEP, Duffy PA, Benvenisty N, et al. Assessing the safety of stem cell therapeutics. Cell Stem Cell  2011; 8(6): 618-28.
 [http://dx.doi.org/10.1016/j.stem.2011.05.012]

[103]
Nakagawa M, Takizawa N, Narita M, Ichisaka T, Yamanaka S. Promotion of direct reprogramming by transformation-deficient Myc. Proc Natl Acad Sci  2010; 107(32): 14152-7.
 [http://dx.doi.org/10.1073/pnas.1009374107]

[104]
Talluri TR, Kumar D, Glage S, Garrels W, Ivics Z, Debowski K, et al. Derivation and characterization of bovine induced pluripotent stem cells by transposon-mediated reprogramming. Cell Reprogramming  2015; 34(4): e15028.
 [http://dx.doi.org/10.1089/cell.2014.0080]

[105]
Shams F, Rahimpour A, Vahidnezhad H, et al. The utility of dermal fibroblasts in treatment of skin disorders: A paradigm of recessive dystrophic epidermolysis bullosa. Dermatol Ther  2021; 34(4): e15028.

[106]
Yu J, Hu K, Smuga-Otto K, et al. Human induced pluripotent stem cells free of vector and transgene sequences. Science  2009; 324(5928): 797-801.
 [http://dx.doi.org/10.1126/science.1172482]

[107]
Stadtfeld M, Nagaya M, Utikal J, Weir G, Hochedlinger K. Induced pluripotent stem cells generated without viral integration. Science  2008; 322(5903): 945-9.
 [http://dx.doi.org/10.1126/science.1162494]

[108]
Shi Y, Desponts C, Do JT, Hahm HS, Schöler HR, Ding S. Induction of pluripotent stem cells from mouse embryonic fibroblasts by Oct4 and Klf4 with small-molecule compounds. Cell Stem Cell  2008; 3(5): 568-74.
 [http://dx.doi.org/10.1016/j.stem.2008.10.004]

[109]
Warren L, Manos PD, Ahfeldt T, et al. Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell  2010; 7(5): 618-30.
 [http://dx.doi.org/10.1016/j.stem.2010.08.012]

[110]
Zhou H, Wu S, Joo JY, et al. Generation of induced pluripotent stem cells using recombinant proteins. Cell Stem Cell  2009; 4(5): 381-4.
 [http://dx.doi.org/10.1016/j.stem.2009.04.005]

[111]
Kumar D, Talluri TR, Anand T, Kues WA. Induced pluripotent stem cells: Mechanisms, achievements and perspectives in farm animals. World J Stem Cells  2015; 7(2): 315.
 [http://dx.doi.org/10.4252/wjsc.v7.i2.315]

[112]
Kumar D, Talluri TR, Anand T, Kues WA. Transposon-based reprogramming to induced pluripotency. Histol Histopathol  2015; 30(12): 1397.

[113]
Davis RP, Nemes C, Varga E, et al. Generation of induced pluripotent stem cells from human foetal fibroblasts using the sleeping beauty transposon gene delivery system. Differentiation  2013; 86(1-2): 30-7.
 [http://dx.doi.org/10.1016/j.diff.2013.06.002]

[114]
Wang Y, Liu J, Jiang Q, et al. Human adipose‐derived mesenchymal stem cell‐secreted CXCL1 and CXCL8 facilitate breast tumor growth by promoting angiogenesis. Stem Cells  2017; 35(9): 2060-70.
 [http://dx.doi.org/10.1002/stem.2643]

[115]
Paino F, La Noce M, Di Nucci D, Nicoletti GF, Salzillo R, De Rosa A, et al. Human adipose stem cell differentiation is highly affected by cancer cells both in vitro and in vivo: Implication for autologous fat grafting. Cell Death Dis  2018; 8(1): e2568.
 [http://dx.doi.org/10.1038/cddis.2016.308]

[116]
Ingulli E. Mechanism of cellular rejection in transplantation. Pediatr Nephrol  2010; 25(1): 61-74.
 [http://dx.doi.org/10.1007/s00467-008-1020-x]

[117]
Marino J, Paster J, Benichou G. Allorecognition by T lymphocytes and allograft rejection. Front Immunol  2016; 7: 582.
 [http://dx.doi.org/10.3389/fimmu.2016.00582]

[118]
Otsuka R, Wada H, Murata T, Seino K. Immune reaction and regulation in transplantation based on pluripotent stem cell technology. Inflamm Regen  2020; 40(1): 12.
 [http://dx.doi.org/10.1186/s41232-020-00125-8]

[119]
Joswig AJ, Mitchell A, Cummings KJ, et al. Repeated intra-articular injection of allogeneic mesenchymal stem cells causes an adverse response compared to autologous cells in the equine model. Stem Cell Res Ther  2017; 8(1): 42.
 [http://dx.doi.org/10.1186/s13287-017-0503-8]

[120]
Lohan P, Treacy O, Griffin MD, Ritter T, Ryan AE. Anti-donor immune responses elicited by allogeneic mesenchymal stem cells and their extracellular vesicles: Are we still learning? Front Immunol  2017; 8: 1626.
 [http://dx.doi.org/10.3389/fimmu.2017.01626]

[121]
Lukomska B, Stanaszek L, Zuba-Surma E, Legosz P, Sarzynska S, Drela K. Challenges and controversies in human mesenchymal stem cell therapy. Int J Stem Cells  2019; 9628536.
 [http://dx.doi.org/10.1155/2019/9628536]

[122]
Ankrum JA, Ong JF, Karp JM. Mesenchymal stem cells: Immune evasive, not immune privileged. Nat Biotechnol  2014; 32(3): 252-60.
 [http://dx.doi.org/10.1038/nbt.2816]

[123]
Zhou BO, Yue R, Murphy MM, Peyer JG, Morrison SJ. Leptin-receptor-expressing mesenchymal stromal cells represent the main source of bone formed by adult bone marrow. Cell Stem Cell  2014; 15(2): 154-68.
 [http://dx.doi.org/10.1016/j.stem.2014.06.008]

[124]
Méndez-Ferrer S, Michurina TV, Ferraro F, et al. Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. Nature  2010; 466(7308): 829-34.

[125]
Shi Y, Hu G, Su J, et al. Mesenchymal stem cells: A new strategy for immunosuppression and tissue repair. Cell Res  2010; 20(5): 510-8.
 [http://dx.doi.org/10.1038/cr.2010.44]

[126]
Thin Luu N, Mcgettrick HM, Buckley CD, et al. Crosstalk between mesenchymal stem cells and endothelial cells leads to downregulation of cytokine‐induced leukocyte recruitment. Stem Cells  2013; 31(12): 2690-702.
 [http://dx.doi.org/10.1002/stem.1511]

[127]
Ren G, Zhao X, Wang Y, et al. CCR2-dependent recruitment of macrophages by tumor-educated mesenchymal stromal cells promotes tumor development and is mimicked by TNFα. Cell Stem Cell  2012; 11(6): 812-24.
 [http://dx.doi.org/10.1016/j.stem.2012.08.013]

[128]
Qi K, Li N, Zhang Z, Melino G. Tissue regeneration: The crosstalk between mesenchymal stem cells and immune response. Cell Immunol  2018; 326: 86-93.
 [http://dx.doi.org/10.1016/j.cellimm.2017.11.010]

[129]
Cho KA, Lee JK, Kim YH, Park M, Woo SY, Ryu KH. Mesenchymal stem cells ameliorate B-cell-mediated immune responses and increase IL-10-expressing regulatory B cells in an EBI3-dependent manner. Cell Mol Immunol  2017; 14(11): 895-908.
 [http://dx.doi.org/10.1038/cmi.2016.59]

[130]
Galleu A, Riffo-Vasquez Y, Trento C, et al. Apoptosis in mesenchymal stromal cells induces in vivo recipient-mediated immunomodulation. Sci Transl Med  2017; 9(416): eaam7828.
 [http://dx.doi.org/10.1126/scitranslmed.aam7828]

[131]
Zarniko N, Skorska A, Steinhoff G, David R, Gaebel R. Dose-independent therapeutic benefit of bone marrow stem cell transplantation after mi in mice. Biomedicines  2020; 8(6): 157.
 [http://dx.doi.org/10.3390/biomedicines8060157]

[132]
Marks PW, Witten CM, Califf RM. Clarifying stem-cell therapy’s benefits and risks. N Engl J Med  2017; 376(11): 1007-9.
 [http://dx.doi.org/10.1056/NEJMp1613723]

[133]
Pittenger MF, Discher DE, Péault BM, Phinney DG, Hare JM, Caplan AI. Mesenchymal stem cell perspective: Cell biology to clinical progress. NPJ Regener Med  2019; 4(1): 1-15.

[134]
Lazarus HM, Koc ON, Devine SM, et al. Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. Biol Blood Marrow Transplant  2005; 11(5): 389-98.
 [http://dx.doi.org/10.1016/j.bbmt.2005.02.001]

[135]
Huang XP, Sun Z, Miyagi Y, et al. Differentiation of allogeneic mesenchymal stem cells induces immunogenicity and limits their long-term benefits for myocardial repair. Circulation  2010; 122(23): 2419-29.
 [http://dx.doi.org/10.1161/CIRCULATIONAHA.110.955971]

[136]
Zhang J, Huang X, Wang H, et al. The challenges and promises of allogeneic mesenchymal stem cells for use as a cell-based therapy. Stem Cell Res Ther  2015; 6(1): 234.
 [http://dx.doi.org/10.1186/s13287-015-0240-9]

[137]
Gu LH, Zhang TT, Li Y, Yan HJ, Qi H, Li FR. Immunogenicity of allogeneic mesenchymal stem cells transplanted via different routes in diabetic rats. Cell Mol Immunol  2015; 12(4): 444-55.
 [http://dx.doi.org/10.1038/cmi.2014.70]

[138]
Schira J, Falkenberg H, Hendricks M, et al. Characterization of regenerative phenotype of unrestricted somatic stem cells (USSC) from human umbilical cord blood (hUCB) by functional secretome analysis. Mol Cell Proteomics  2015; 14(10): 2630-43.
 [http://dx.doi.org/10.1074/mcp.M115.049312]

[139]
Winter M, Wang XN, Däubener W, et al. Suppression of cellular immunity by cord blood‐derived unrestricted somatic stem cells is cytokine‐dependent. J Cell Mol Med  2009; 13(8b): 2465-75.
 [http://dx.doi.org/10.1111/j.1582-4934.2008.00566.x]

[140]
Fishman JA. Overview: Cytomegalovirus and the herpesviruses in transplantation. Am J Transplant  2013; 13(s3): 1-8.
 [http://dx.doi.org/10.1111/ajt.12002]

[141]
Preynat-Seauve O, de Rham C, Tirefort D, Ferrari-Lacraz S, Krause KH, Villard J. Neural progenitors derived from human embryonic stem cells are targeted by allogeneic T and natural killer cells. J Cell Mol Med  2009; 13(9b): 3556-69.
 [http://dx.doi.org/10.1111/j.1582-4934.2009.00746.x]

[142]
Weeden CE, Asselin-Labat ML. Mechanisms of DNA damage repair in adult stem cells and implications for cancer formation. Biochim Biophys Acta Mol Basis Dis  2018; 1864(1): 89-101.
 [http://dx.doi.org/10.1016/j.bbadis.2017.10.015]

[143]
He S, Sharpless NE. Senescence in health and disease. Cell  2017; 169(6): 1000-11.
 [http://dx.doi.org/10.1016/j.cell.2017.05.015]

[144]
Xu M, Pirtskhalava T, Farr JN, et al. Senolytics improve physical function and increase lifespan in old age. Nat Med  2018; 24(8): 1246-56.
 [http://dx.doi.org/10.1038/s41591-018-0092-9]

[145]
Drela K, Stanaszek L, Nowakowski A, Kuczynska Z, Lukomska B. Experimental strategies of mesenchymal stem cell propagation: Adverse events and potential risk of functional changes. Stem Cells Int  2019; 7012692.
 [http://dx.doi.org/10.1155/2019/7012692]

[146]
Li Y, Wu Q, Wang Y, Li L, Bu H, Bao J. Senescence of mesenchymal stem cells. Int J Mol Med  2017; 39(4): 775-82.
 [http://dx.doi.org/10.3892/ijmm.2017.2912]

[147]
DiGirolamo CM, Stokes D, Colter D, Phinney DG, Class R, Prockop DJ. Propagation and senescence of human marrow stromal cells in culture: A simple colony-forming assay identifies samples with the greatest potential to propagate and differentiate. Br J Haematol  1999; 107(2): 275-81.
 [http://dx.doi.org/10.1046/j.1365-2141.1999.01715.x]

[148]
Stab BR, Martinez L, Grismaldo A, et al. Mitochondrial functional changes characterization in young and senescent human adipose derived MSCs. Front Aging Neurosci  2016; 8: 299.
 [http://dx.doi.org/10.3389/fnagi.2016.00299]

[149]
Coste C, Neirinckx V, Sharma A, et al. Human bone marrow harbors cells with neural crest-associated characteristics like human adipose and dermis tissues. PLoS One  2017; 12(7): e0177962.
 [http://dx.doi.org/10.1371/journal.pone.0177962]

[150]
Li P, Guo X. A review: Therapeutic potential of adipose-derived stem cells in cutaneous wound healing and regeneration. Stem Cell Res Ther  2018; 9(1): 302.
 [http://dx.doi.org/10.1186/s13287-018-1044-5]

[151]
Yang YHK, Ogando CR, Wang See C, Chang TY, Barabino GA. Changes in phenotype and differentiation potential of human mesenchymal stem cells aging in vitro. Stem Cell Res Ther  2018; 9(1): 131.
 [http://dx.doi.org/10.1186/s13287-018-0876-3]

[152]
Khong SML, Lee M, Kosaric N, et al. Single‐cell transcriptomics of human mesenchymal stem cells reveal age‐related cellular subpopulation depletion and impaired regenerative function. Stem Cells  2019; 37(2): 240-6.
 [http://dx.doi.org/10.1002/stem.2934]

[153]
Adegani FJ, Langroudi L, Arefian E, Shafiee A, Dinarvand P, Soleimani M. A comparison of pluripotency and differentiation status of four mesenchymal adult stem cells. Mol Biol Rep  2013; 40(5): 3693-703.
 [http://dx.doi.org/10.1007/s11033-012-2445-7]

[154]
Quyyumi AA, Waller EK, Murrow J, et al. CD34+ cell infusion after ST elevation myocardial infarction is associated with improved perfusion and is dose dependent. Am Heart J  2011; 161(1): 98-105.
 [http://dx.doi.org/10.1016/j.ahj.2010.09.025]

[155]
van der Spoel TIG, Jansen of Lorkeers SJ, Agostoni P, et al. Human relevance of pre-clinical studies in stem cell therapy: Systematic review and meta-analysis of large animal models of ischaemic heart disease. Cardiovasc Res  2011; 91(4): 649-58.
 [http://dx.doi.org/10.1093/cvr/cvr113]

[156]
Iwasaki H, Kawamoto A, Ishikawa M, et al. Dose-dependent contribution of CD34-positive cell transplantation to concurrent vasculogenesis and cardiomyogenesis for functional regenerative recovery after myocardial infarction. Circulation  2006; 113(10): 1311-25.
 [http://dx.doi.org/10.1161/CIRCULATIONAHA.105.541268]

[157]
Hare JM, Fishman JE, Gerstenblith G, et al. Comparison of allogeneic vsautologous bone marrow–derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: The POSEIDON randomized trial. JAMA  2012; 308(22): 2369-79.
 [http://dx.doi.org/10.1001/jama.2012.25321]

[158]
Hamamoto H, Gorman JH III, Ryan LP, Hinmon R, Martens TP, Schuster MD, et al. Allogeneic mesenchymal precursor cell therapy to limit remodeling after myocardial infarction: The effect of cell dosage. Ann Thorac Surg  2009; 87(3): 794-801.
 [http://dx.doi.org/10.1016/j.athoracsur.2008.11.057]

[159]
Golpanian S, DiFede DL, Khan A, et al. Allogeneic human mesenchymal stem cell infusions for aging frailty. J Gerontol A Biol Sci Med Sci  2017; 72(11): 1505-12.
 [http://dx.doi.org/10.1093/gerona/glx056]

[160]
Packham DK, Fraser IR, Kerr PG, Segal KR. Allogeneic mesenchymal precursor cells (MPC) in diabetic nephropathy: A randomized, placebo-controlled, dose escalation study. EBioMedicine  2016; 12: 263-9.
 [http://dx.doi.org/10.1016/j.ebiom.2016.09.011]

[161]
Melmed GY, Pandak WM, Casey K, et al. Human placenta-derived cells (PDA-001) for the treatment of moderate-to-severe Crohn’s disease: A phase 1b/2a study. Inflamm Bowel Dis  2015; 21(8): 1809-16.
 [http://dx.doi.org/10.1097/MIB.0000000000000441]

[162]
Kabat M, Bobkov I, Kumar S, Grumet M. Trends in mesenchymal stem cell clinical trials 2004-2018: Is efficacy optimal in a narrow dose range? Stem Cells Transl Med  2020; 9(1): 17-27.
 [http://dx.doi.org/10.1002/sctm.19-0202]

[163]
Golpanian S, Schulman IH, Ebert RF, et al. Concise review: Review and perspective of cell dosage and routes of administration from preclinical and clinical studies of stem cell therapy for heart disease. Stem Cells Transl Med  2016; 5(2): 186-91.
 [http://dx.doi.org/10.5966/sctm.2015-0101]

[164]
Strauer BE, Brehm M, Zeus T, et al. Repair of infarcted myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans. Circulation  2002; 106(15): 1913-8.
 [http://dx.doi.org/10.1161/01.CIR.0000034046.87607.1C]

[165]
Perin EC, Dohmann HFR, Borojevic R, et al. Transendocardial, autologous bone marrow cell transplantation for severe, chronic ischemic heart failure. Circulation  2003; 107(18): 2294-302.
 [http://dx.doi.org/10.1161/01.CIR.0000070596.30552.8B]

[166]
Wei X, Yang X, Han Z, Qu F, Shao L, Shi Y. Mesenchymal stem cells: A new trend for cell therapy. Acta Pharmacol Sin  2013; 34(6): 747-54.
 [http://dx.doi.org/10.1038/aps.2013.50]

[167]
Hu X, Wang J, Chen J, et al. Optimal temporal delivery of bone marrow mesenchymal stem cells in rats with myocardial infarction. Eur J Cardiothorac Surg  2007; 31(3): 438-43.
 [http://dx.doi.org/10.1016/j.ejcts.2006.11.057]

[168]
Rigol M, Solanes N, Roura S, et al. Allogeneic adipose stem cell therapy in acute myocardial infarction. Eur J Clin Invest  2014; 44(1): 83-92.
 [http://dx.doi.org/10.1111/eci.12195]

[169]
Cho PS, Messina DJ, Hirsh EL, et al. Immunogenicity of umbilical cord tissue–derived cells. Blood Am J Hematol  2008; 111(1): 430-8.

[170]
Kim DW, Staples M, Shinozuka K, Pantcheva P, Kang SD, Borlongan C. Wharton’s jelly-derived mesenchymal stem cells: Phenotypic characterization and optimizing their therapeutic potential for clinical applications. Int J Mol Sci  2013; 14(6): 11692-712.
 [http://dx.doi.org/10.3390/ijms140611692]

[171]
Biazar E, Heidari Keshel S. Electrospun poly (3-hydroxybutyrate-co-3-hydroxyvalerate)/hydroxyapatite scaffold with unrestricted somatic stem cells for bone regeneration. ASAIO J  2015; 61(3): 357-65.
 [http://dx.doi.org/10.1097/MAT.0000000000000205]

[172]
Semenov OV, Koestenbauer S, Riegel M, et al. Multipotent mesenchymal stem cells from human placenta: Critical parameters for isolation and maintenance of stemness after isolation. Am J Obstet Gynecol  2010; 202(2): 193.e1-e13.
 [http://dx.doi.org/10.1016/j.ajog.2009.10.869]

[173]
Cubillo EJ, Ngo SM, Juarez A, Gagan J, Lopez GD, Stout DA. Embryonic stem cell therapy applications for autoimmune, cardiovascular, and neurological diseases: A review. AIMS Cell Tissue Eng  2017; 1(3): 191.

[174]
Shroff G, Titus JD, Shroff R. A review of the emerging potential therapy for neurological disorders: Human embryonic stem cell therapy. Am J Stem Cells  2017; 6(1): 1.

[175]
Shroff G. A review on stem cell therapy for multiple sclerosis: Special focus on human embryonic stem cells. Stem Cells Cloning  2018; 11: 1-11.
 [http://dx.doi.org/10.2147/SCCAA.S135415]

[176]
King NMP, Perrin J. Ethical issues in stem cell research and therapy. Stem Cell Res Ther  2014; 5(4): 85.
 [http://dx.doi.org/10.1186/scrt474]

[177]
Swijnenburg RJ, Schrepfer S, Govaert JA, et al. Immunosuppressive therapy mitigates immunological rejection of human embryonic stem cell xenografts. Proc Natl Acad Sci  2008; 105(35): 12991-6.
 [http://dx.doi.org/10.1073/pnas.0805802105]

[178]
Jung YW, Hysolli E, Kim KY, Tanaka Y, Park IH. Human induced pluripotent stem cells and neurodegenerative disease. Curr Opin Neurol  2012; 25(2): 125-30.
 [http://dx.doi.org/10.1097/WCO.0b013e3283518226]

[179]
Blelloch R, Venere M, Yen J, Ramalho-Santos M. Generation of induced pluripotent stem cells in the absence of drug selection. Cell Stem Cell  2007; 1(3): 245-7.
 [http://dx.doi.org/10.1016/j.stem.2007.08.008]

[180]
Yang M, Liu Y, Hou W, et al. Mitomycin C-treated human-induced pluripotent stem cells as a safe delivery system of gold nanorods for targeted photothermal therapy of gastric cancer. Nanoscale  2017; 9(1): 334-40.
 [http://dx.doi.org/10.1039/C6NR06851K]

[181]
Anguera MC, Sadreyev R, Zhang Z, et al. Molecular signatures of human induced pluripotent stem cells highlight sex differences and cancer genes. Cell Stem Cell  2012; 11(1): 75-90.
 [http://dx.doi.org/10.1016/j.stem.2012.03.008]

[182]
Eminli S, Foudi A, Stadtfeld M, et al. Differentiation stage determines potential of hematopoietic cells for reprogramming into induced pluripotent stem cells. Nat Genet  2009; 41(9): 968-76.
 [http://dx.doi.org/10.1038/ng.428]

[183]
Kim K, Doi A, Wen B, et al. Epigenetic memory in induced pluripotent stem cells. Nature  2010; 467(7313): 285-90.
 [http://dx.doi.org/10.1038/nature09342]

[184]
Polo JM, Liu S, Figueroa ME, et al. Cell type of origin influences the molecular and functional properties of mouse induced pluripotent stem cells. Nat Biotechnol  2010; 28(8): 848-55.
 [http://dx.doi.org/10.1038/nbt.1667]

[185]
Doi A, Park IH, Wen B, et al. Differential methylation of tissue- and cancer-specific CpG island shores distinguishes human induced pluripotent stem cells, embryonic stem cells and fibroblasts. Nat Genet  2009; 41(12): 1350-3.
 [http://dx.doi.org/10.1038/ng.471]

[186]
Chin MH, Mason MJ, Xie W, et al. Induced pluripotent stem cells and embryonic stem cells are distinguished by gene expression signatures. Cell Stem Cell  2009; 5(1): 111-23.
 [http://dx.doi.org/10.1016/j.stem.2009.06.008]

[187]
Nelson TJ, Martinez-Fernandez A, Yamada S, Mael AA, Terzic A, Ikeda Y. Induced pluripotent reprogramming from promiscuous human stemness‐related factors. Clin Transl Sci  2009; 2(2): 118-26.
 [http://dx.doi.org/10.1111/j.1752-8062.2009.00091.x]

[188]
Chung L, Cogburn LA, Sui L, Dashnau JL. Development of an induced pluripotent stem cell–specific microRNA assay for detection of residual undifferentiated cells in natural killer cell therapy products. Cytotherapy  2022; 24(7): 733-41.
 [http://dx.doi.org/10.1016/j.jcyt.2022.02.005]

[189]
Sato Y, Bando H, Di Piazza M, et al. Tumorigenicity assessment of cell therapy products: The need for global consensus and points to consider. Cytotherapy  2019; 21(11): 1095-111.
 [http://dx.doi.org/10.1016/j.jcyt.2019.10.001]
Cite As
Current Stem Cell Research & Therapy

Recent Emerging Trend in Stem Cell Therapy Risk Factors

Abstract

Graphical Abstract
